--- title: "Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies | MRM Stock News" description: "MEDIROM Healthcare Technologies Inc. announced a capital and business alliance with NFES Technologies Inc., with NFES Group as the lead investor in MOTHER Labs' Series A financing round, valuing it at" type: "news" locale: "en" url: "https://longbridge.com/en/news/212422757.md" published_at: "2024-08-24T01:12:00.000Z" --- # Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies | MRM Stock News > MEDIROM Healthcare Technologies Inc. announced a capital and business alliance with NFES Technologies Inc., with NFES Group as the lead investor in MOTHER Labs' Series A financing round, valuing it at 9 billion yen. The agreement includes launching the MOTHER Bracelet, a health monitoring device, and expanding sales through NFES Group's distribution channels. MEDIROM anticipates this partnership will attract additional investors for MOTHER Labs' growth and business development strategies. 08/23/2024 - 09:12 PM **NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen** TOKYO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; CEO: Koji Eguchi; listed on Nasdaq, NASDAQ: MRM; hereinafter “MEDIROM”) announces that its subsidiary MEDIROM MOTHER Labs Inc. (Headquarters: Minato-ku, Tokyo; CEO: Yoshio Uekusa; hereinafter “MOTHER Labs”), has formed a capital and business alliance with NFES Technologies Inc. (Headquarters: Matsue City, Shimane Prefecture; CEO: Keita Adachi; hereinafter “NFES Group”), a subsidiary of NFES Inc. (Headquarters: Matsue City, Shimane Prefecture; CEO: Keita Adachi). As part of this alliance, NFES Group has agreed to participate as the lead investor in MOTHER Labs’ Series A financing round, which values MOTHER Labs at 9 billion yen on a pre-money basis. The Series A shares will be issued to NFES Group as a third-party allotment. **◾️Background of the Capital and Business Alliance** The NFES Group is committed to creating a world where individuals can passionately pursue what they love. They resonate with MOTHER Labs’ dedication to global challenges as a Japanese company and the concept behind the MOTHER Bracelet, a recharge-free smart tracker designed to monitor people’s health. This shared vision led to the capital and business alliance, with the aim of collaborating with MOTHER Labs to promote the MOTHER Bracelet and support the health of people worldwide. **◾️Future Initiatives** We have concluded a distributorship agreement for MOTHER Bracelet, the recharge-free smart tracker developed by the MEDIROM group, and MOTHER Gateway, MEDIROM’s telecommunication device which exclusively enables data generated by MOTHER Bracelet to be sent to our proprietarily developed remote monitoring system, and will introduce these products to companies in the nursing care, transportation, and manufacturing industries and promote their introduction through collaborations with financial institutions and sales partners allied with NFES Group. In addition, MOTHER Labs will also collaborate with Hyakkaten.com (a regional department store e-commerce mall operated by NFES Group) to conduct general sales through department stores and e-commerce sites nationwide. With NFES Group participating as the lead investor in this Series A round, we anticipate attracting additional investors, allowing us to secure the necessary funds for MOTHER Labs’ business expansion and facilitating the company’s further business development. **◾️Sales Structure** The NFES Group has established a new company, NFES Technologies Inc., specializing in sales of MOTHER Bracelet and plans to expand sales both domestically and internationally as the designated main distributor of MOTHER Bracelet products. **Forward-Looking Statements Regarding MEDIROM and MOTHER Labs** Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include: - MEDIROM’s ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives; - MEDIROM’s and NFES Group’s ability to collaborate in the anticipated manner and on the expected terms; - MOTHER Labs’ ability to secure additional investors in its Series A financing round on acceptable terms, or at all; - changes in Japanese and global economic conditions and financial markets, including their effects on MEDIROM’s expansion in Japan and certain overseas markets; - MEDIROM’s ability to achieve and sustain profitability in its Digital Preventative Healthcare Segment; - the fluctuation of foreign exchange rates, which affects MEDIROM’s expenses and liabilities payable in foreign currencies; - MEDIROM’s ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property; - MEDIROM’s ability to raise additional capital on acceptable terms or at all; - MEDIROM’s level of indebtedness and potential restrictions on MEDIROM under MEDIROM’s debt instruments; - changes in consumer preferences and MEDIROM’s competitive environment; - MEDIROM’s ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and - the regulatory environment in which MEDIROM operates. More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future. **■MEDIROM MOTHER Labs Inc.** MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM Healthcare Technologies Inc., primarily focuses on the health tech sector. The company’s core activities include the “Specific Health Guidance Program” offered through the “Lav” health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. The tracker’s popularity raised a record-breaking 56.1 million yen on the Japanese crowdfunding platform “Makuake”. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc. ・Company Overview Company Name: MEDIROM MOTHER Labs Inc. Headquarters: Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo Representative: Kouji Eguchi, Yoshio Uekusa Establishment: July 2023 Business Area: Health Tech Business / Device Business / Software Services **■About MEDIROM Healthcare Technologies Inc.** ・Company Overview Company Name: MEDIROM Healthcare Technologies Inc. Listed Market: NASDAQ Ticker Symbol: MRM Headquarters: Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo CEO/Founder: Kouji Eguchi Establishment: July 2000 URL: https://medirom.co.jp/en **◾️About NFES Technologies Inc.** NFES Technologies Inc. is a health tech company established as a subsidiary of NFES Corporation, which develops creative business. The company will develop its business centered on sales and system linkage of the MOTHER Bracelet smart tracker, which requires no recharging 24 hours a day, 365 days a year, and the MOTHER Gateway telecommunication device. Company name: NFES Technologies, Inc. Head Office: Shimane Bank Head Office Building 11F, 484-19 Asahi-cho, Matsue City, Shimane Prefecture Representative: Keita Adachi, CEO Establishment: July 2024 Business: Health tech business URL: https://nfes-tech.com **◾️About NFES Inc.** Company name: NFES Inc. Head Office: Shimane Bank Head Office Bldg. 11F, 484-19 Asahi-cho, Matsue City, Shimane Prefecture Representative: Keita Adachi, CEO Establishment: May 2022 Business description: Creative business URL: https://nfes.fun Contacts Investor Relations Team ir@medirom.co.jp Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/733fb149-5951-4cd8-8eff-36a9480f8d75 https://www.globenewswire.com/NewsRoom/AttachmentNg/5208a192-b2b6-4eeb-9991-cd0bb357947f https://www.globenewswire.com/NewsRoom/AttachmentNg/f4ab65e0-2b41-4982-90a1-5d9c19f4e9d5 https://www.globenewswire.com/NewsRoom/AttachmentNg/9e3433cd-4f86-4c26-bdc9-3cd916359712 https://www.globenewswire.com/NewsRoom/AttachmentNg/2fbe48d1-176e-40b4-a927-2652a4a14235 https://www.globenewswire.com/NewsRoom/AttachmentNg/4a44978d-ea5e-40d1-9e7b-0440f39791bb ### Related Stocks - [MRM.US - Medirom Healthcare Tech](https://longbridge.com/en/quote/MRM.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Medirom Healthcare Technologies 发行了 2.75 亿日元的可转换债券 | Medirom Healthcare Technologies Inc. 已发行 2.75 亿日元的无担保可转换债券，由 Kufu Company Holdings Inc. 认购，销售于 2025 年 12 月 31 日完成。此次发行是在 | [Link](https://longbridge.com/en/news/274799476.md) | | Medirom Healthcare Technologies 报告 2025 年 12 月每位客户的销售额创下纪录，重复购买率达到 77.8% | Medirom Healthcare Technologies Inc. 在 2025 年 12 月报告了每位客户创纪录的销售额为 7,926 日元，超过行业平均水平 3,120 日元。该公司服务了 70,499 名客户，实现了 77.8% | [Link](https://longbridge.com/en/news/274503916.md) | | 特朗普暗示违法征收的关税不退了，美财长称今年关税收入将 “基本保持不变” | 美国总统特朗普暗示不会退还被最高法院裁定违法的关税，预计 2026 年关税收入将保持不变。特朗普计划签署行政令，对全球商品加征 10% 进口关税，取代被推翻的关税。财长贝森特表示，政府将利用替代法律权力维持关税收入，强调国家安全和财政收入不 | [Link](https://longbridge.com/en/news/276494362.md) | | 都想学英伟达 “芯片换融资”，谷歌和 AMD 都要扶持 “AI 云” | 谷歌正试图复制英伟达的成功路径，利用金融实力构建芯片生态系统。公司正洽谈向 “新型云” 公司 Fluidstack 注资约 1 亿美元，并为 Hut 8 等转型矿企提供项目融资支持，以换取 TPU 芯片的采用。AMD 则更为激进，为初创公司 | [Link](https://longbridge.com/en/news/276502552.md) | | 最高法裁决后特朗普动用替补选择：加征 10% 全球关税 | 美国总统特朗普在最高法院裁决后宣布将加征 10% 的全球关税，以补救被推翻的关税措施。根据《1974 年贸易法》第 122 条款，现有的关税将全面生效。最高法院裁定特朗普政府的部分关税措施缺乏法律授权。市场风险提示，投资需谨慎。 | [Link](https://longbridge.com/en/news/276477629.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.